Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05706558

Retrospective Review of Esophageal Cancer at MSKCC

Residual tumor at the proximal or distal margin after esophagectomy is a known prognostic factor for poor survival outcomes in patients with esophageal cancer; however, the significance of the circumferential resection margin (CRM) remains controversial. In this study, the investigators sought to evaluate the prognostic significance of the CRM in patients with esophageal cancer undergoing resection.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Esophageal Cancer Digestive System Diseases Digestive System Neoplasms Esophageal Diseases Esophageal Neoplasms Esophagus Cancer Gastrointestinal Diseases Gastrointestinal Neoplasms Head and Neck Neoplasms Neoplasms Neoplasms by Site

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, 10065, United States

Location status: Recruiting

Location contact

Daniela Molena, MD

CONTACT

212-639-3870

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically confirmed esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy
  • Pathologic staged T3 tumors (pT3)

Exclusion criteria

  • Pathologic staged T0-2 (pT0-2) or T4 tumors (pT4)
  • Patients with histologic types other than EAC or ESCC, dysplasia or carcinoma in situ without tumor invasion,
  • Patients undergoing salvage esophagectomy
  • Evidence of distant metastatic disease
  • Patients with a positive proximal or distal margin

Treatment and study plan

Esophagectomy

Procedure

Esophagectomy

Primary outcomes

  1. . Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery)

    Time frame: Up to 2 years

    Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery) and the association between patient characteristics, neoadjuvant therapy, and postoperative morbidity.

Secondary outcomes

  1. Overall survival and progression-free survival (measured from date of surgery)

    Time frame: Up to 2 years

    Postoperative outcomes stratified by the type of esophageal cancer surgery performed.

  2. Postoperative outcomes stratified by the time between neoadjuvant therapy and surgery (i.e., delayed or immediate).

    Time frame: Up to 2 years

  3. Survival outcomes stratified by treatment modality (i.e., definitive chemoradiation therapy or trimodality treatment).

    Time frame: Up to 2 years

  4. Survival outcomes stratified by use of adjuvant therapy (i.e., adjuvant therapy or no adjuvant therapy).

    Time frame: Up to 2 years

Study contacts

Contact information is provided by the study sponsor or research team.

Daniela Molena, MD

CONTACT

[email protected]

212-639-3870

James Isbell, MD

CONTACT

[email protected]

212-639-6247

Sponsors and collaborators

Lead sponsor

Memorial Sloan Kettering Cancer Center

Other

Registry information

Important dates

Study start
2016
Primary completion
2027
Study completion
2027
First posted
Jan 31, 2023
Registry last updated
Mar 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.